Long-term efficacy of evolocumab in reducing lipids in EU subjects with and without type 2 diabetes: an analysis from the open-label extension OSLER studies
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Conference item |
| Published: |
Springer Verlag
2016
|
| _version_ | 1797080343438688256 |
|---|---|
| author | Sattar, N Valensi, P Preiss, D Dent, R Bridges, I Ruzza, A Cyrille, M Handelsman, Y |
| author_facet | Sattar, N Valensi, P Preiss, D Dent, R Bridges, I Ruzza, A Cyrille, M Handelsman, Y |
| author_sort | Sattar, N |
| collection | OXFORD |
| description | |
| first_indexed | 2024-03-07T00:58:38Z |
| format | Conference item |
| id | oxford-uuid:88f41bfc-5c34-4c54-85c4-fb2cf385df9d |
| institution | University of Oxford |
| last_indexed | 2024-03-07T00:58:38Z |
| publishDate | 2016 |
| publisher | Springer Verlag |
| record_format | dspace |
| spelling | oxford-uuid:88f41bfc-5c34-4c54-85c4-fb2cf385df9d2022-03-26T22:21:10ZLong-term efficacy of evolocumab in reducing lipids in EU subjects with and without type 2 diabetes: an analysis from the open-label extension OSLER studiesConference itemhttp://purl.org/coar/resource_type/c_5794uuid:88f41bfc-5c34-4c54-85c4-fb2cf385df9dSymplectic Elements at OxfordSpringer Verlag2016Sattar, NValensi, PPreiss, DDent, RBridges, IRuzza, ACyrille, MHandelsman, Y |
| spellingShingle | Sattar, N Valensi, P Preiss, D Dent, R Bridges, I Ruzza, A Cyrille, M Handelsman, Y Long-term efficacy of evolocumab in reducing lipids in EU subjects with and without type 2 diabetes: an analysis from the open-label extension OSLER studies |
| title | Long-term efficacy of evolocumab in reducing lipids in EU subjects with and without type 2 diabetes: an analysis from the open-label extension OSLER studies |
| title_full | Long-term efficacy of evolocumab in reducing lipids in EU subjects with and without type 2 diabetes: an analysis from the open-label extension OSLER studies |
| title_fullStr | Long-term efficacy of evolocumab in reducing lipids in EU subjects with and without type 2 diabetes: an analysis from the open-label extension OSLER studies |
| title_full_unstemmed | Long-term efficacy of evolocumab in reducing lipids in EU subjects with and without type 2 diabetes: an analysis from the open-label extension OSLER studies |
| title_short | Long-term efficacy of evolocumab in reducing lipids in EU subjects with and without type 2 diabetes: an analysis from the open-label extension OSLER studies |
| title_sort | long term efficacy of evolocumab in reducing lipids in eu subjects with and without type 2 diabetes an analysis from the open label extension osler studies |
| work_keys_str_mv | AT sattarn longtermefficacyofevolocumabinreducinglipidsineusubjectswithandwithouttype2diabetesananalysisfromtheopenlabelextensionoslerstudies AT valensip longtermefficacyofevolocumabinreducinglipidsineusubjectswithandwithouttype2diabetesananalysisfromtheopenlabelextensionoslerstudies AT preissd longtermefficacyofevolocumabinreducinglipidsineusubjectswithandwithouttype2diabetesananalysisfromtheopenlabelextensionoslerstudies AT dentr longtermefficacyofevolocumabinreducinglipidsineusubjectswithandwithouttype2diabetesananalysisfromtheopenlabelextensionoslerstudies AT bridgesi longtermefficacyofevolocumabinreducinglipidsineusubjectswithandwithouttype2diabetesananalysisfromtheopenlabelextensionoslerstudies AT ruzzaa longtermefficacyofevolocumabinreducinglipidsineusubjectswithandwithouttype2diabetesananalysisfromtheopenlabelextensionoslerstudies AT cyrillem longtermefficacyofevolocumabinreducinglipidsineusubjectswithandwithouttype2diabetesananalysisfromtheopenlabelextensionoslerstudies AT handelsmany longtermefficacyofevolocumabinreducinglipidsineusubjectswithandwithouttype2diabetesananalysisfromtheopenlabelextensionoslerstudies |